Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of Obrixtamig (BI 764532) Combined With Ezabenlimab in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3

NCT05879978 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05879978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05879978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of Obrixtamig (BI 764532) Combined With Ezabenlimab in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 27, 2023
Completion date
March 31, 2027
Enrollment
45 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine neoplasms, small cell lung carcinoma (sclc)